Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months Jul 13, 2008
The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. (PR Newswire)
Childhood Rashes & RNA Virus Infect... Jul 13, 2008
Complications may include ear infection, encephalitis, pneumonia, diarrhea or vomiting, bronchitis and thrombocytopenia. At Risk. (Suite101.com)
Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity Jun 26, 2008
IL-1beta, IL-8, TNF-alpha and MCP-1 were associated with marked thrombocytopenia. Increased MCP-1 and GM-CSF levels correlated with hypotension. (BioMed Central)
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma Jun 21, 2008
The safety profile of VELCADE in combination with MP is consistent with the known safety profiles of both VELCADE and MP. In VISTA, the most commonly reported adverse events for VELCADE in combination with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia... (PR Newswire)
Blood Cancer Drug Shows Promise Against Lupus Jun 10, 2008
"Autoantibody-mediated diseases such as autoimmune hemolytic anemia, immune thrombocytopenia, myasthenia gravis and systemic lupus erythematosus are often difficult to treat," said lead researcher Dr. Reinhard Voll, of the University of Erlangen-Nuremberg. A big problem is that plasma cells, which are the predominant producers of the disease-causing autoantibodies, can't be efficiently attacked with current treatments, Voll said. (MEDLINEplus)
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma Jun 5, 2008
Hematologic toxicities included 29 percent grade 3/4 neutropenia, with 7 percent being grade 4, 46 percent grade 3 thrombocytopenia, and 18 percent grade 3 anemia ... The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. (PR Newswire)
Clinical study shows biological and clinical activity in relapsed leukemia patients Jun 5, 2008
None of the patients had myelotoxicities, such as neutropenia, lymphopenia or thrombocytopenia, associated with GCS-100. The most common adverse event was rash, which was generally self-limiting and mild-to-moderate in severity. (EurekAlert!)
Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma Jun 2, 2008
The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion- related toxicities were associated with pre-administration of rituximab. (PR Newswire)
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer Jun 2, 2008
The dose limiting toxicity (DLT) for the every-four-week regimen at 180 mg/m2 was hematologic with neutropenia and thrombocytopenia as the most frequent adverse events. The maximum tolerated dose (MTD) in the every-four-week FOLPI schedule was previously reported to be hematologic and occurred at 150 mg/m2. (PR Newswire)
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma Jun 1, 2008
0063) -- 63 percent of patients did not require a second transplantation compared to 44 percent (p/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%) ... The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%) ... The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). (PR Newswire)
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma Jun 1, 2008
Side effects included thrombocytopenia, neutropenia, hyperglycemia and peripheral neuropathy ... Side effects were manageable and included lymphopenia, thrombocytopenia, hypophosphatemia and neutropenia ... Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. (PR Newswire)
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma Jun 1, 2008
The most frequently occurring grade 3 or 4 adverse events among patients treated with TORISEL 175 mg/75 mg, TORISEL 175 mg/25 mg, or IC were thrombocytopenia (59 percent vs. 52 percent vs. 36 percent of patients, respectively), anemia (20 percent vs. 11 percent vs. 17 percent), neutropenia (15 percent vs. 22 percent vs. 26 percent) and asthenia (13 percent vs. 19 percent vs. 8 percent) ... The most common laboratory abnormalities (incidence greater than or equal to 30%) are anemia (94%),... (PR Newswire)
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer Jun 1, 2008
The most common laboratory abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased... (PR Newswire)
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer Jun 1, 2008
In contrast to picoplatin monotherapy, thrombocytopenia was less severe and less frequent. Neurotoxicity has not been observed in this study. (PR Newswire)
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting May 16, 2008
Adverse events included two Grade 3 dose- limiting toxicities (upper respiratory infection (URI) and elevated liver enzymes) and five cases of Grade 3 thrombocytopenia (low-platelet count) without any sign of bleeding. Reductions in platelet counts were analyzed in the three ongoing Phase I trials as a biomarker of Bcl-2 family protein inhibition. (PR Newswire)
Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting May 16, 2008
The most commonly occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit or for full prescribing information. (PR Newswire)
Complications of Liver Cirrhosis May 11, 2008
Liver cirrhosis is associated with other complications, including anemia, low platelets in the blood (thrombocytopenia), proneness to bleeding due to diminished clotting factors (coagulopathy), and hepatocellular carcinoma. Final Words. (Suite101.com)
Immunotherapy: Enlisting The Immune System To Fight Cancer Apr 19, 2008
The most common side effects were thrombocytopenia (low platelet count) and neutropenia (low white blood cell count). Side effects were deemed tolerable. (Science Daily)
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales Apr 10, 2008
Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome ... VELCADE is associated with thrombocytopenia and neutropenia ... In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%),... (PR Newswire)
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases Mar 21, 2008
6%), thrombocytopenia (Grade 3: 7. 0%), infection (Grade 3: 6. (PR Newswire)
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma Mar 17, 2008
Grade 3/4 thrombocytopenia, neutropenia, and anemia occurred in 63 percent (36 of 57), 53 percent (30 of 57), and 23 percent (13 of 57), respectively ... The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. (PR Newswire)
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma Mar 5, 2008
The toxicity associated with Zevalin included severe (grade 3 or 4) hematologic toxicity in 12 of 20 patients; the most common severe side effects were neutropenia (12 patients) and thrombocytopenia (7 patients) ... The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. (PR Newswire)
Web video maker hopes his antics pave way to stardom Feb 19, 2008
He was born with Thrombocytopenia Absent Radii, also called TAR syndrome. He knows people either laugh or turn away in disgust, accusing him of exploiting his disability for a laugh. (Daytona Beach News Journal)
Recovery means uncovering a past buried for years Feb 3, 2008
Low platelet count or thrombocytopenia: This is caused by low levels of vitamin B12 and folic acid, and sometimes by excessive alcohol consumption. It can also be a sign of a suppressed or dysfunctional immune system. (Daytona Beach News Journal)
Rigel Announces Pricing of Public Offering of Common Stock Feb 1, 2008
We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer. This press release contains "forward-looking" statements, including statements related to Rigel's plans to complete a public offering and its strategy to further develop a portfolio of product candidates. (PR Newswire)
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer Jan 28, 2008
The dose limiting toxicity (DLT) was most frequently hematological with neutropenia and thrombocytopenia. The maximum tolerated dose was established in the every-four-week schedule at 150 mg/m squared. (PR Newswire)
FDA Approves Additional Indication for Astellas' MYCAMINE(R) Jan 23, 2008
The most common treatment-emergent adverse events include diarrhea, nausea, vomiting, pyrexia, hypokalemia, thrombocytopenia and headache. About Astellas Pharma US, Inc. Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. (PR Newswire)
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent Jan 22, 2008
The most common greater than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 patients). "This single arm, non-randomized phase II trial provides additional insights into the potential utility of RIT in intermediate grade NHL, a subtype where CRs are infrequent with rituximab therapy," noted Jack W. Singer, M.D., Chief Medical Officer of CTI. The study results are reported in the current issue of CANCER at Study Details Between February 2005 and June... (PR Newswire)
Fritz Cubin tends antiques, heals from surgeries Dec 17, 2007
Among other illnesses, he has had thrombocytopenia, a condition of a deficient number of circulating blood platelets, the cells that help blood to clot, Rep. Cubin s office said in a statement in July. (Casper Star-Tribune, WY)
Ireland Cancer Center researchers advance stem cell gene therapy Dec 13, 2007
Dr. Shigemi Matsuyama and colleagues presented a novel way of treating chemotherapy -induced thrombocytopenia (decrease in number of platelets in the blood) using Bax Inhibiting Peptides to rescue the damaged cells. Dr. Keith McCrae and colleagues presented that 2 glycoprotein is a cofactor in the process that dissolves blood clots through the use of the medical agent tPA.. (EurekAlert!)
Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 Dec 10, 2007
The common adverse reactions associated with the use of Thalidomide in combination with other anti-myeloma therapies are: deep vein thrombosis, constipation, peripheral edema, tremor, dizziness, fatigue, asthenia, somnolence, peripheral neuropathy, neutropenia, lymphopenia, leucopenia, anemia, thrombocytopenia, paraesthesia and dysaesthesia. Serious or severe reactions associated with Thalidomide use are: deep vein thrombosis and pulmonary embolism, bradycardia, cerebrovascular accident,... (PR Newswire)
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting Dec 10, 2007
Adverse events (AE) associated with MGCD0103 administration of grade 3 or higher included pneumonia (15 percent), and thrombocytopenia (12 percent) and fatigue (9 percent) ... Among the 50 patients evaluable for safety at time of analysis, the most common drug-related toxicities grade 3 or higher were fatigue (14 percent), neutropenia (12 percent), thrombocytopenia (10 percent) and anemia (6 percent). (PR Newswire)
Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment Dec 10, 2007
6%- 48%), anemia (1%-42%), thrombocytopenia ( (1) Known as Glivec(R) (imatinib) outside the U.S., Canada and Israel. (2) Numbers indicate the range of percentages in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. (PR Newswire)
Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS) Dec 10, 2007
These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL) ... 5%), thrombocytopenia (65 ... Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed... (PR Newswire)
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash Dec 9, 2007
Common toxicities associated with bortezomib included thrombocytopenia (Grade 3-4 at 1. 3 mg/m2) and neuropathy (Grade 1-2, at 1. (PR Newswire)
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Dec 9, 2007
Adult ITP is a serious chronic autoimmune disorder characterized by low platelet counts in the blood, a condition known as thrombocytopenia ... Amgen has recently filed for regulatory approval of romiplostim for use in the treatment of thrombocytopenia in adults with chronic ITP in the United States (U.S.), European Union (EU), Australia and Canada ... Adult Immune (idiopathic) thrombocytopenic purpura (ITP) is a chronic and serious autoimmune disorder characterized by low levels of platelets in... (BusinessWire)
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH) Dec 9, 2007
Based on its strong potency, convenience and potential for dosing flexibility, we believe that LGD-4665 could be used as treatment for a wide variety of diseases associated with thrombocytopenia, including hepatitis C, chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases ... Thrombocytopenia Market Opportunity ... Thrombocytopenia is seen in 5-10% of all patients hospitalized for any... (BusinessWire)
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity Dec 9, 2007
Two patients experienced dose-limiting toxicities (transient AST elevation and thrombocytopenia). The most common drug-related adverse events among all patients were nausea (n=14), thrombocytopenia (n=13), diarrhea (n=12), vomiting (n=12), fatigue (n=10) anemia (n=6) and neutropenia (n=6) ... Based on these initial results presented for the first time, Merck is evaluating plans to accelerate testing of ZOLINZA in combination with bortezomib in the randomized clinical trial setting to further... (EurekAlert!)
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting Dec 8, 2007
Do not substitute for doxorubicin HCl on a mg per mg basis Contraindications -- Patients with a history of hypersensitivity reactions to a conventional doxorubicin formulation or the components of DOXIL -- Nursing mothers Additional Safety Information -- Cardiac function should be carefully monitored -- Congestive heart failure or cardiomyopathy may occur after discontinuation of anthracycline therapy -- For patients with a history of cardiovascular disease, or if the results of cardiac... (PR Newswire)
MIKE STARRY: Voters must ask for care we need Dec 8, 2007
In October 2006, Dr. A. Mustajeeb Haseeb of Cancer Care Associates sent me to Saint Agnes Medical Center for treatment of the life-threatening disease idiopathic thrombocytopenia, low blood platelets' count. Normal is between 150,000 and 450,000. (Fresno Bee -- Opinion)
Drug May Help Reverse Clotting Deficiency Nov 30, 2007
Thrombocytopenia, which refers to any disorder in which there are not enough platelets, can prevent people from receiving necessary treatments. With ITP, the body destroys its own platelets or not enough platelets are produced. (MEDLINEplus)
Eltrombopag for Thrombocytopenia in Cirrhosis Nov 29, 2007
NEJM -- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C ... Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C ... We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis. (New England Journal of Medicine)
Continuous-Flow Ventricular Assist Device Nov 29, 2007
Although antithrombotic therapy and the risk of thromboembolism are mentioned in the discussion, can the authors comment on heparin use, the incidence of thrombocytopenia, and subsequent evaluation for heparin-induced thrombocytopenia that may have ensued. In a series of 92 consecutive patients receiving a left ventricular assist device (LVAD) before cardiac transplantation, the incidence of heparin-induced thrombocytopenia was 26 ... 2 Do the authors believe that there may be an association... (New England Journal of Medicine)
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Nov 22, 2007
3% in the placebo group), thrombocytopenia (11. 4% vs. 5. (New England Journal of Medicine)
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia Nov 14, 2007
LEUVEN, Belgium, November 14 /PRNewswire/ -- - Key Research Findings Published in the Leading Medical Journal `Blood' Validate Drug Target ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today that it will progress with the development of its novel anti-VPAC(1) antibody for the treatment of thrombocytopenia, including chemotherapy-induced thrombocytopenia. Thrombocytopenia, which is the reduced number of platelets in blood, is a common... (PR Newswire)
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML Nov 9, 2007
In this same study, the frequency of Grade 3/4 neutropenia, thrombocytopenia, and anemia was 34%, 22%, and 10%, respectively, in the SPRYCEL 100 mg once-daily group and 43%, 38%, and 17%, respectively, in the SPRYCEL 70 mg twice-daily group ... In this same study, the frequency of Grade 3/4 neutropenia, thrombocytopenia, and anemia was 63%, 56%, and 19%, respectively, in the SPRYCEL group and 39%, 14%, and 8%, respectively, in the Gleevec group ... IMPORTANT SAFETY INFORMATION Myelosuppression:... (PR Newswire)
Taxotere Improves Survival in Head-Neck Cancer Oct 27, 2007
Taxotere tended to cause more loss of hair and infection-fighting white blood cells but less nausea and thrombocytopenia, which can produce excessive bleeding. "I frankly feel we can cure about 70 percent of patients with this kind of combination chemotherapy and chemoradiation therapy," Posner said. (MEDLINEplus)
CORRECTION FROM SOURCE: MethylGene and Pharmion Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference Oct 26, 2007
In addition, grade 4 hyperkalemia and thrombocytopenia were reported in one patient. Based on determination of the recommended Phase II dose of 90mg and clinical activity, the Phase II portion of the trial has been initiated in gemcitabine-naive patients with metastatic or non-resectable locally-advanced pancreatic cancer. (CCNMatthews Press Releases)
TPF Therapy in Unresectable Head and Neck Cancer Oct 25, 2007
There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group. The rates of death from toxic effects were 2. (New England Journal of Medicine)
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan Oct 22, 2007
In the pancreatic cancer trial, other serious adverse events associated with Tarceva plus gemcitabine and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia. When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding. (BusinessWire)
Antiphospholipid Syndrome Oct 21, 2007
Cytomegalovirus (CMV) is associated with arterial damage, and the development of Raynaud s phenomena, whereas has been associated with hematological changes such as severe anemia, low white blood cells (leucopenia) and platelet deficiencies (thrombocytopenia). No significant association has been made with the Epstein-Barr virus (EBV). (Suite101.com)
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis Oct 15, 2007
"We are very impressed with the consistency of these data and feel that they continue to point to the strong likelihood of alemtuzumab being approved for MS patients." Safety Data: No New Cases of ITP A total of six patients have been diagnosed with ITP associated with Grade 3 or 4 thrombocytopenia in this trial and there have been no new cases of ITP reported in the past year in this study ... The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever,... (PR Newswire)
Cubin injures foot at WMC Oct 8, 2007
Dr. Frederick "Fritz" Cubin has been in and out of the hospital over the last six months after being diagnosed with thrombocytopenia, which causes sufferers to have a deficient number of circulating blood platelets. He was most recently admitted to the Casper hospital Wednesday. (Casper Star-Tribune, WY)
Taxotere Gets FDA Approval For Advance Head And Neck Cancer Before ... Oct 2, 2007
-- grade 3/4 thrombocytopenia in the TPF group 4% -- grade 3/4 thrombocytopenia in the PF group 11. -- stomatitis in the TPF group 21% -- stomatitis in the PF group 27. (Medical News Today)
Both Cubins leave hospital Sep 27, 2007
Fritz Cubin has been in and out of the hospital for the past six months after being diagnosed with thrombocytopenia, a condition in which there are not enough blood platelets, cells that help blood clot, circulating in the body. He had previously been released from the hospital at the end of July. (Casper Star-Tribune, WY)
Korn comeback| Sep 23, 2007
The belligerence has been replaced by some self-reflection no doubt the result of frontman's Jonathan Davis' brush with death after developing the potentially fatal blood disease idiopathic thrombocytopenia purpura that's most notable on 'I Will Protect You. Dedicated to his sons, the strongest connection to their past (and the only song to feature his beloved bagpipes) is a storm of angelic backing vocals, militant drumming, and atmospheric keyboard swathes that descends into menacing... (iAfrica.com)
Aspreva Provides Update On Lupus Nephritis Development Program Sep 10, 2007
Adverse events reported in greater than 30% of renal, cardiac or liver transplant patients receiving CellCept (in combination with cyclosporine and corticosteroids) were pain, fever, headache, asthenia, anemia, leucopenia (patients should be monitored for neutropenia; dosing should be interrupted or the dose reduced if neutropenia develops), thrombocytopenia, leukocytosis, urinary tract infection, hypertension, hypotension, peripheral edema, hypercholesteremia, hypokalemia, hyperglycemia,... (Primezone Releases)
A systematic review of cooling for neuroprotection in neonates with hypoxic ischemic encephalopathy - are we there yet? Sep 5, 2007
87) and thrombocytopenia (RR: 1. 47, 95% CI: 1. (BioMed Central)
Nine-year-old boy plays ball for ill brother Aug 31, 2007
As an infant Ryan, now 5, was diagnosed with an extremely rare ailment known as cutaneous angio-mitosis with thrombocytopenia. Ryan is just one of 10 patients worldwide who have been diagnosed with the illness, which leaves tumors on the patient's lungs, upper and lower gastro-intestinal tract, liver and bone marrow. (Seacoast New Hampshire)
MGI Pharma gets rights to blood disorder drug Aug 30, 2007
AKR-501 treats a condition called thrombocytopenia, which often leads to abnormal bleeding in patients suffering from diseases like cancer, hepatitis C, or an autoimmune disorder. MGI also said it plans to begin studies in patients with hepatitis C and with cancer patients who are being treated with chemotherapy. (Twin Cities Business Journal, MN)
Stocks to Watch Aug 29, 2007
MGI Pharma Inc. () said it has agreed to acquire the development rights to AKR-501, a molecule being developed for the treatment of thrombocytopenia, from AkaRx Inc. Thrombocytopenia is characterized by an abnormally low level of circulating platelets. Under the agreement, MGI has also obtained an option to acquire AkaRx at any time up to Jan. 8, 2010. (Fox News)
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States Aug 16, 2007
The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. (PR Newswire)
Drug Effective In Treatment Of Heavy Psoriasis Patients Aug 5, 2007
The most serious side effects experienced by patients in trials with RAPTIVA (efalizumab) were low platelet counts (thrombocytopenia), low blood counts (anemia), new or worsening psoriasis, and new or worsening arthritis. Because RAPTIVA is an immunosuppressive agent, it has the potential to increase the risk of infection and cancer. (Science Daily)
Hospital releases Cubin's husband Jul 31, 2007
He had been diagnosed with thrombocytopenia, a condition in which there is a deficient number of circulating blood platelets, the cells that help blood clot, her office said in a statement at the time of the first surgery. The congresswoman vowed to remain at her husband s side in Casper until his condition significantly improved. (Casper Star-Tribune, WY)
Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy Jul 11, 2007
Positive interim results prompt request for meeting with FDA SEATTLE, July 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: ; MTAX) announced today that interim results of its phase II/III trial comparing CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R first-line treatment of patients with aggressive non-Hodgkin's lymphoma (NHL), resulted in essentially all patients on both arms achieving a major objective anti-tumor response (complete response or... (PR Newswire)
